Compare · COR vs SCNX
COR vs SCNX
Side-by-side comparison of Cencora Inc. (COR) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $53.51B, about 3658.4x SCNX ($14.6M).
- Over the past year, COR is down 3.5% and SCNX is down 65.7% - COR leads by 62.2 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- COR has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- Cencora Inc.
- Scienture Holdings Inc.
- Price
- $274.12-0.34%
- $0.36-0.58%
- Market cap
- $53.51B
- $14.6M
- 1M return
- +7.25%
- -11.22%
- 1Y return
- -3.48%
- -65.66%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SD filed by Cencora Inc.
- Director Durcan Dermot Mark bought $1,065,040 worth of shares (4,000 units at $266.26), increasing direct ownership by 17% to 27,767 units (SEC Form 4)
- Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
- Cencora Announces Updated Fiscal Year 2026 Financial Outlook
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Second Quarter Results
- Director Tyler Lauren M was granted 99 shares, increasing direct ownership by 3% to 3,809 units (SEC Form 4)
- Director Cooper Ellen was granted 99 shares, increasing direct ownership by 14% to 796 units (SEC Form 4)
Latest SCNX
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits